24/7 Market News Snapshot 01 November, 2024 – Pediatrix Medical Group, Inc. (NYSE:MD)

November 1, 2024

DENVER, Colo., 01 November, 2024 (247marketnews.com) – (NYSE:MD) are discussed in this article.
Pediatrix Medical Group, Inc. (MD) has experienced a notable surge in its stock price, opening at $13.80 and climbing to $14.60, representing an impressive increase of 18.51% from the previous close of $12.32. This significant uptick in share price reflects heightened investor interest and strong trading volume, currently at 898.84K shares. Market analysts observe this momentum as a potential breakout, contingent on the continuation of buying activity. Key technical indicators suggest that support is positioned around $13.80, with resistance identified at $15.00, prompting investors to closely monitor volume trends that may indicate further volatility and asset allocation opportunities.

In a related financial update, Pediatrix reported its third-quarter results for the period ending September 30, 2024. The company posted net revenues of $511 million, marking a modest year-over-year increase, with net income rising to $19 million or $0.23 per share. Additionally, the adjusted earnings per share (EPS) climbed to $0.44, up from $0.32 in the same quarter last year. This growth was driven by a 5.2% rise in same-unit revenue, largely attributed to improvements in payor mix and enhanced hospital contract administrative fees.

CEO James D. Swift, M.D. emphasized that the company’s operational results have surpassed expectations, highlighting its dedication to refining revenue cycle management and streamlining its portfolio of services. Furthermore, Pediatrix transitioned successfully to a hybrid revenue cycle management model, resulting in an adjusted EBITDA of $60 million, a significant increase from the previous year’s $50 million.

Pediatrix also announced plans to divest from most office-based practices by year-end, projecting an annual positive impact of approximately $30 million on adjusted EBITDA, which aligns with its strategic focus on pediatrics and obstetrics services. The company forecasts its full-year adjusted EBITDA for 2024 to range between $205 million and $215 million, indicating a strong outlook for continued growth and financial stability.

Related news for (MD)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.